Bionor Pharma ASA
About Bionor Pharma ASA
Bionor Pharma is a leading vaccine company, listed on the Oslo Stock Exchange. Their technology is based on more than two decades of peptide research where peptide vaccines are designed to safely stimulate each person’s immune system to more effectively combat viral diseases.
Bionor Pharma`s vaccine development started with a focus on HIV/AIDS.
Global leader in developing HIV vaccine: The Company’s lead investigational product, the therapeutic HIV vaccine Vacc-4x, has shown a statistically significant reduction in viral load in a phase IIb randomized, multinational (USA, Germany, UK, Spain and Italy), placebo controlled, double-blind study.
A step towards long lasting HIV viral control with Vacc-4x: Conventional HIV medication (antiretroviral therapy, ART) is not a cure, but blocks virus production only while patients take this medication. ART must therefore be a lifelong treatment. In contrast, Bionor Pharma’s therapeutic HIV vaccine aims to induce long lasting virus control by training immune cells to seek out and kill virus-producing cells. The observed 64% reduction in viral load in patients who received Vacc-4x compared to placebo in the phase IIb study therefore represents a step towards long-lasting viral control. HIV vaccine inducing antibodies: Bionor`s second therapeutic HIV vaccine, Vacc-C5 is developed to induce antibodies to HIV that can reduce the harmful hyperactivation of the immune system that leads to AIDS.
Global HIV challenge: According to the UN organization UNAIDS, 34 million people were living with HIV in 2010. Approximately three million new people are infected annually. Only one out of six HIV infected patients currently has access to ART treatment.
Pathways to market for Bionor Pharma`s HIV vaccines: Bionor researchers will investigate various independent pathways to market for the HIV vaccine candidates through further clinical studies:
1. Vacc-4x revaccination in patients who participated in the phase IIb study, with the aim of reducing viral load even further.
2. Vacc-4x combined with Revlimid® (lenalidomide), in patients with a weakened immune system which does not recover despite having a well-controlled viral load on ART.
3. Vacc-C5 clinical trial, to document whether Vacc-C5 increases HIV antibodies in humans. The company aims to subsequently study Vacc-C5 in combination with Vacc-4x, a treatment that potentially can eradicate and prevent HIV and thereby revolutionize HIV treatment.
Nasal administration of Vacc-4x: A placebo controlled study with Vacc-4x at Oslo University Hospital demonstrated safety, and successful immunization in treated patients. This may offer an easier treatment access for HIV patients globally.
Other viral diseases
The Company’s innovative technology platform is also well suited for the development of vaccines for other viral diseases, such as Influenza, hepatitis C (HCV), cervical cancer (HPV, Human Papilloma Virus) and cytomegalovirus infection (CMV).